Recent Articles from GlobeNewswire

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today announced that (i) on October 20, 2025, one new employee was granted an inducement award consisting of a stock option to purchase 23,602 shares of common stock, (ii) on October 28, 2025, three new employees were granted inducement awards consisting of stock options to purchase an aggregate of 49,849 shares of common stock and (iii) on November 3, 2025, one new employee was granted an inducement award consisting of a stock option to purchase 14,766 shares of common stock.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In KBR To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Jasper (JSPR) To Contact Him Directly To Discuss Their Options

SPARTANBURG, S.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Denny’s Corporation (the "Company") (NASDAQ: DENN), owner and operator of Denny's Inc. ("Denny's") and Keke's Inc. ("Keke's") today announced that it will no longer hold its third quarter earnings conference call originally scheduled for 4:30 p.m. Eastern Time today in light of the announced transaction with TriArtisan Capital Advisors LLC, Treville Capital Group and Yadav Enterprises, Inc.

Denny’s Stockholders to Receive $6.25 Per Share in Cash, Delivering Significant, Near-Term and Certain Cash Value

LISLE, Ill., Nov. 03, 2025 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE: CTS) announced today that the company will participate in the 17th Annual Southwest IDEAS Conference on November 20, 2025, at The Westin Las Colinas in Dallas, TX. CTS’s presentation is scheduled to begin at 4:00 PM Central Time.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Fortinet (FTNT) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In RCI (RICK) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Quanex (NYSE:NX) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Cytokinetics (CYTK) To Contact Him Directly To Discuss Their Options

This novel therapy offers the first FDA-approved option to address the root cause of this ultra-rare condition, which causes progressive muscle weakness impairing walking, breathing, and swallowing.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Fluor (FLR) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Lantheus (LNTH) To Contact Him Directly To Discuss Their Options

BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences:

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In V.F. Corporation (VFC) To Contact Him Directly To Discuss Their Options

Board-Certified OB-GYN Discusses Evidence-Based Tools to Help Women Navigate Their Midlife Transitions

Enhances geographic footprint and scale

VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) announces that pursuant to the Company's stock option plan, 7,151,055 incentive stock options exercisable at $0.19 per share for a period of five years have been granted to directors, officers, employees and consultants of the Company.

Hong Kong, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Skyline Builders Group Holding Limited (NASDAQ: SKBL) (the “Company”), a civil engineering services provider in Hong Kong, today announced that on November 3, 2025 (the “Closing Date”) it closed its previously announced private placement (the “Private Placement”) of 17,370,909 Class A Ordinary Shares and/or Prefunded Warrants in lieu of Class A Ordinary Shares , together with Class A Ordinary Share Purchase Warrants to purchase up to 17,370,909 Class A Ordinary Shares (the “Ordinary Warrants") at a purchase price for a combination of one Class A Ordinary Share and one Ordinary Warrant of $1.375 and a purchase price for a combination of one Prefunded Warrant and one Ordinary Warrant of $1.37499, for combined aggregate gross proceeds of approximately $23,885,000, before deducting placement agent fees and other offering expenses payable by the Company.

The firm’s new financial model aligns with Bitcoin’s institutional surge and XRP’s regulatory comeback.

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Viking Acquisition Corp. I (NYSE: VACI.U) (the “Company” or “Viking”), a Cayman Islands exempted company, announced today the closing of its initial public offering of 23,000,000 units at a price of $10.00 per unit, including an additional 3,000,000 units sold pursuant to the full exercise of the underwriters’ over-allotment option, for gross proceeds of $230 million. Each unit consists of one (1) Class A ordinary share and one-third (1/3) of one redeemable warrant, with each whole warrant exercisable to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. Only whole warrants will be exercisable.

TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- McEwen Inc. (NYSE/TSX: MUX) (“McEwen”, "MUX" or the "Company”) invites you to join our conference call following the release of our Q3 2025 financial results. The call will take place on Thursday, November 6, 2025 at 11:00 AM EST. Management will discuss our financial results and project developments and follow with a question-and-answer session. Participants can ask questions directly over the phone during the webcast.

― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ―

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Guggenheim Investments today announced that certain closed-end funds have declared their distributions. The table below summarizes the distribution schedule for each closed-end fund (collectively, the “Funds” and each, a “Fund”).

EDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, November 7, 2025, at 8:30 AM (ET) to present its Q3 2025 financial results.

WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective November 1, 2025, the company granted a non-qualified stock option to purchase 5,700 shares of its common stock to one new employee under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

SINGAPORE, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Antalpha Platform Holding Company (NASDAQ: ANTA) ("Antalpha" or the "Company"), a leading institutional digital asset financing platform, today announced that it will report its financial results for the third quarter of 2025 before the U.S. market open on November 10, 2025. The Company’s management team will hold a conference call at 8:00 A.M. U.S. Eastern Time on Novemebr 10, 2025 (or 9:00 P.M. Singapore Time on November 10, 2025) to discuss the financial results.

SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Cabot Corporation (NYSE: CBT) today announced that Robert Rist has been appointed Vice President of Investor Relations and Corporate Planning. The transition will take place over the course of the first quarter of fiscal year 2026. In this expanded role, Rist succeeds Steve Delahunt, who will continue with the company as Vice President of Treasury.

Fourth Quarter 2025 Diluted earnings per share (“EPS”) of $0.79 and Adjusted EPS of $1.70Fiscal Year 2025 Diluted EPS of $6.02 and Adjusted EPS of $7.25

NEWPORT NEWS, Va., Nov. 03, 2025 (GLOBE NEWSWIRE) -- HII (NYSE: HII) announced today that Tim Taylor has been appointed vice president of engineering, technology and design at its Newport News Shipbuilding division.

Chatillion, France, November 3, 2025

DAVIDSON, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ingersoll Rand Inc., (NYSE: IR) a global provider of mission-critical flow creation and life science and industrial solutions, today announced the acquisition of Transvac Systems Ltd. (“Transvac”), a United Kingdom-based global supplier of ejector solutions and sustainable process technologies used to move, mix, and compress fluids and gases. Transvac will join the Industrial Technologies and Services (IT&S) segment.

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The Boards of Trustees/Directors of the PIMCO closed-end funds below (each, a “Fund” and, collectively, the “Funds”) have declared a monthly distribution for each Fund’s common shares as summarized below.

FRISCO, TX, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Comstock Resources, Inc. ("Comstock" or the "Company") (NYSE; NYSE Texas: CRK) today reported financial and operating results for the quarter ended September 30, 2025.

Robust Cash Flow Generation Driven by Increased Scale, Operational Synergies, and Asset Optimization Strategy

PARIS and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences:

Key Highlights

Achieves record quarterly revenue of $201.7 million in Q3 2025

Diversified Energy Announces Third Quarter Dividend

IRVINE, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at two upcoming investor conferences (all Eastern Time):

Delivered Q3 2025 revenue of $83 million

CINCINNATI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Mobile Infrastructure Corporation (NASDAQ: BEEP), the nation’s only publicly traded owner of parking infrastructure, will issue its third quarter 2025 earnings release after the U.S. market closes on Monday, November 10, 2025.

All results reported are for continuing operations, unless otherwise noted.

Nyxoah to Participate in the Stifel 2025 Healthcare Conference

PEMBROKE, Bermuda, Nov. 03, 2025 (GLOBE NEWSWIRE) -- James River Group Holdings, Ltd. ("James River" or the "Company") (NASDAQ: JRVR) reported a net loss from continuing operations available to common shareholders of $0.4 million, or ($0.01) per diluted share, compared to a net loss from continuing operations available to common shareholders of ($40.7 million), or ($1.07) per diluted share, for the same 2024 period. Adjusted net operating income1 for the third quarter of 2025 was $17.4 million or $0.32 per diluted share, compared to ($28.2 million), or ($0.74) per diluted share, for the same 2024 period.

Highlights

MALVERN, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MALVERN, Pa., November 3, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of William (“Bill”) Plovanic, CFA, to its Board of Directors.

The Special Meeting of Shareholders reconvenes on November 7, 2025

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis

Cambridge, Massachusetts, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, and members of senior management will be participating in a fireside chat and investor one-on-one meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference on Monday, November 10th, 2025 in Boston, MA.

VISTA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Flux Power Holdings, Inc. (NASDAQ: FLUX), a leading developer of advanced lithium-ion energy storage solutions and software-driven electrification for commercial and industrial equipment, will report its fiscal first quarter 2026 results on Thursday, November 13, 2025, after market close. Krishna Vanka, Chief Executive Officer, and Kevin Royal, Chief Financial Officer, will host a conference call at 4:30 p.m. ET to discuss the Company’s financial results, followed by a question-and-answer session.

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences in November 2025:

Validation study data show AdvanceAD-Tx can identify patients with AD who have a ‘JAKi responder profile’ and a superior response to JAKi therapies compared to Th2-targeted therapies

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in November:

STRATEGIC PORTFOLIO EXPANSION AND STRONG PRODUCT SEGMENT PERFORMANCE DROVE REVENUE AND EARNINGS GROWTH

Global Aesthetics Leader Brings Deep Industry Expertise and Proven Track Record Driving Growth Across Health, Beauty, and Consumer Sectors

HUNTSVILLE, Ala., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lakeland Industries, Inc. (“Lakeland Fire + Safety” or “Lakeland”) (NASDAQ: LAKE), a leading global manufacturer of protective clothing and apparel for industry, healthcare and first responders, today announced that its Board of Directors declared a cash dividend for its fiscal fourth quarter of 2026 of $0.03 per share. The dividend will be paid on November 24, 2025, to stockholders of record as of November 17, 2025.

TARRYTOWN, N.Y., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

DENVER, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), appoints Paul Taheri, MD, MBA as its Chief Medical Officer, effective November 3, 2025.

The virtual webcast will take place Wednesday, November 12, 2025, at 8 a.m. ET

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- EverQuote, Inc. (Nasdaq: EVER), a leading online insurance marketplace, today announced financial results for the third quarter ended September 30, 2025.

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in a presentation at the Jefferies Global Healthcare Conference on Monday, November 17, at 2:30 p.m. GMT.  

BANNOCKBURN, Ill., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will participate in the following upcoming investor conferences:

TORRANCE, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Navitas Semiconductor (Nasdaq: NVTS), the industry leader in next-generation GaNFast™ gallium nitride (GaN) and GeneSiC™ high-voltage silicon carbide (SiC) power semiconductors, today announced unaudited financial results for the third quarter ended September 30, 2025.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Nidec (NJDCY) To Contact Him Directly To Discuss Their Options

NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, November 6, 2025, at 8:30 a.m. ET to discuss its third quarter 2025 financial results and provide a corporate update.

Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024;

– Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete 

New collaboration brings together Rapid7’s SOC expertise with Microsoft’s security ecosystem to simplify operations, strengthen protection, and unlock new value for joint customers

Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma

Mdxhealth to Release Third Quarter 2025 Financial Resultson November 12

WILMINGTON, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Symbotic Inc. (Nasdaq: SYM), a leader in A.I.-enabled robotics technology for the supply chain, today announced it will release fourth quarter and fiscal year 2025 financial results after the market close on Monday, November 24, 2025. The press release will also be available on the Symbotic Investor Relations website: www.ir.symbotic.com. The company will host a live webcast to discuss its financial results for the quarter at 5:00 p.m. ET on the same date.

– $45.9 million in total revenue, representing 21% growth over 2Q25 –